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Abstract 
Background: In 2011, private pharmacies associated to the Brazilian Ministry of Health provided patients with two 
types of insulin (regular human insulin and isophane insulin or NPH) and three oral antidiabetic medications (5 mg 
glibenclamide and 500 and 850 mg metformin) free of charge. The aim was to evaluate the impact of the “Health Has 
No Price” Program [Saúde Não Tem Preço (SNTP)] for access to diabetes treatment medicines in Brazil.
Methods: This longitudinal and observational study is based on the number of units of oral hypoglycemic agents, 
insulin and insulin analogues supplied in 55,000 private pharmacies from February 1, 2010 to January 31, 2012. The 
number of tablets (oral hypoglycemic agents) and international units (insulins and insulin analogues) supplied in the 
first 12 months of the SNTP Program were compared with the number of tablets and international units supplied in 
the 12 months prior to its implementation.
Results: The insulins in the SNTP program had the highest percentage change in the number of international units 
supplied; regular human insulin increased by 97.8 % and isophane insulin (NPH) by 78.0 %. Among the oral hypogly‑
cemic agents, 5 mg glibenclamide increased by 65.9 %, and 500 and 850 mg metformin increased by 46.8 and 39.9 %, 
respectively, in the number of tablets dispensed in the first year of the SNTP Program. Among the hypoglycemic 
agents not available in SNTP, 4 mg glimepiride had the highest percentage increase in units supplied (19.2 %) in the 
same period. Among the insulin analogues, which were not available in the SNTP Program, insulin glulisine showed 
the greatest increase in units dispensed (34.2 %).
Conclusions: The SNTP Program contributed to increased access to medicines for the treatment of diabetes in Brazil.
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Background
According to the World Health Organization (WHO), 
access to essential medications is one of the five indi-
cators of progress in securing the right to health [1]. 
Although the percentage of the global population with-
out access to essential medications has decreased, 
approximately 1.3–2.1 billion people still lack access to 
essential medications [2, 3]. In developing countries, 
especially in Latin America, larger differences in medica-
tion consumption levels exist between population strata 
[4]. Higher economic classes show consumption patterns 
similar to wealthier countries, while lower economic 
classes have difficulty in accessing basic medications [5].
According to Cameron et  al. [6], even when medica-
tions are provided for free distribution or at low cost 
to the public sector, access is limited as a result of low 
availability. This low availability may result from a com-
bination of factors such as inadequate funding, lack of 
incentives for stock maintenance, the inability to predict 
demand accurately, inefficient distribution systems or 
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Although the Brazilian Public Health System [Sistema 
Único de Saúde (SUS)] has the duty to provide medica-
tions for the treatment of diabetes that are included in 
the national list of essential medicines [7, 8], Bahia et al. 
[9] found that 24.6 % of patients with diabetes in Brazil 
bought their medications from private pharmacies.
To increase access to medications in Brazil, in 2006 the 
state began to subsidize approximately 90  % of the cost 
of drugs used for the treatment of diabetes and hyper-
tension through a co-payment system associated with 
the Ministry of Health that covered medications pur-
chased from private pharmacies [10]. In February 2011, 
this policy was expanded with the creation of the “Health 
Has No Price” Program [Programa Saúde Não Tem Preço 
(SNTP)], in which associated pharmacies began to pro-
vide two types of insulin (regular human insulin and 
isophane insulin or NPH) and three oral antidiabetic 
medications (glibenclamide 5  mg, metformin 500 and 
850 mg) free of charge, with a subsequent reimbursement 
of the amount agreed upon between the government and 
the pharmaceutical industry [11]. In this context, the 
objective of our study was to evaluate the impact of the 
SNTP Program on the access to medications for diabetes 
treatment in Brazil.
Methods
We performed a longitudinal observational study of the 
access to antidiabetic medications in Brazil after the 
implementation of the SNTP Program. Data were col-
lected from 55,000 pharmacies, representing approxi-
mately 76  % of private pharmacy establishments in the 
country, from February 1, 2010 to January 31, 2012 [12]. 
The number of tablets (oral antidiabetic medication) and 
the international units (insulin and insulin analogues) 
supplied free of charge during the first 12  months of 
the SNTP Program were compared with those supplied 
under the co-payment system in the 12 months prior to 
the implementation of the program. The oral antidiabetic 
tablets selected were from two subgroups of the ana-
tomical therapeutic chemical (ATC) WHO classifica-
tion, which consisted of medicines in the SNTP Program 
(biguanides and sulfonylureas). In addition, an insulin 
subgroup was also included in the study. A similar analy-
sis was performed with three fixed-dose combinations 
not included in the SNTP Program (two containing oral 
antidiabetics and one combined with insulin).
Results
The number of supplied units of all medicines for the 
treatment of diabetes in the SNTP Program increased 
in the first 12  months of the SNTP Program compared 
with the 12  months prior to the implementation of the 
program. The percentage of variation ranged from 39.9 
to 97.8  %. Four sulfonylureas (glibenclamide, glimepir-
ide, glipizide and chlorpropamide), one biguanide (met-
formin) and three fixed-dose combinations marketed in 
Brazil were included in the analysis of oral antidiabetic 
medications. The number of tablets supplied in the SNTP 
program increased from 39.9 to 65.9  % in the first year 
of the program. No other oral antidiabetic medication 
showed a comparable increase in the number of units 
supplied. The number of tablets dispensed (none in the 
SNTP Program) of the three fixed-dose combinations 
analyzed decreased after implementation of the SNTP 
Program (Table 1).
A similar evaluation was performed with insulin and 
the insulin analogues marketed in Brazil. The two types 
of insulins included in the SNTP Program showed the 
highest percentage of change in the number of interna-
tional units dispensed, even when compared with the 
oral antidiabetics. The only form of insulin that showed 
a decrease in the number of international units supplied 
after the implementation of the program was the fixed-
dose combination of regular human insulin and isophane 
insulin. Also, the insulin analogues not included in the 
SNTP Program (insulin lispro, glulisine, glargine, aspart 
and detemir) showed an increase in the number of inter-
national units dispensed (Table 2).
Discussion
This is the first study describing the impact of the SNTP 
Program on the access to antidiabetics in Brazil. The 
results confirmed a significant expansion of access to the 
diabetes treatment medications included in the SNTP 
Program, especially compared with other medications 
of the same therapeutic classes that are available in the 
Brazilian market. The analysis of the percentage change 
in the number of oral antidiabetic tablets and the num-
ber of international units of insulin supplied, whether as 
single agents or fixed-dose combinations, indicates that 
access expansion was greater for medicines included in 
the SNTP Program.
It was further observed that a lack of some fixed-dose 
combinations in the SNTP Program may result in the 
prescription of two individual medicines. The four fixed-
dose combinations analyzed and formulated with active 
ingredients of single agents can be obtained at no cost in 
associated pharmacies. These combinations exhibited a 
decrease in the number of units dispensed after the start 
of the SNTP Program. This result may indicate a prefer-
ence for the prescription of medicines available through 
the program.
The implementation of the SNTP Program, through an 
agreement between private pharmacies and the Ministry 
of Health, increased the access to medicines for the treat-
ment of diabetes in Brazil. Also, the number of associated 
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pharmacies increased from 14,003 in December 2010 to 
22,470 establishments in July 2013, covering 3664 cities 
[13, 14].
The initiative by the Ministry of Health to subsi-
dize the purchase of medications in private pharmacies 
began in 2006 through a co-payment system in which the 
Table 1 Number of oral antidiabetics tablets supplied in the first 12 months of the SNTP Program (free of charge) and in 
the 12 months before to the Program (copayment system)
Brazil, February 2010 through January 2012
Adapted from information published [12]
ATC Anatomical therapeutic chemical
a  Only one of the combination of drugs is contemplated in the SNTP Program at the same concentration
b  Both drugs are included in the combination SNTP Program at the same concentrations
Medicines ATC Feb. 2010–Jan. 2011 Feb. 2011–Jan. 2012 Percentage 
of charge
Medicines included in SNTP Program
 Glibenclamide 5 mg A10BB01 158,388,380 262,747,850 65.9
 Metformin 500 mg A10BA02 289,027,638 424,146,878 46.8
 Metformin 850 mg A10BA02 283,321,454 396,338,216 39.9
Medicines not included in SNTP Program
 Single‑drug formulations
  Glimepiride 4 mg A10BB12 38,372,010 45,749,970 19.2
  Metformin 1000 mg A10BA02 12,940,380 14,202,110 9.8
  Glimepiride 2 mg A10BB12 63,221,310 67,166,190 6.2
  Glipizide 5 mg A10BB07 1,415,340 1,300,020 −8.2
  Chlorpropamide 250 mg A10BB02 17,151,540 14,763,550 −13.9
Fixed‑dose combinations
 Glibenclamide + metformin (1 mg + 500 mg)a A10BD02 25,764,510 22,236,330 −13.7
 Glibenclamide + metformin (5 mg + 500 mg)b A10BD02 41,330,990 36,197,800 −12.4
 Glibenclamide + metformin (2,5 mg + 500 mg)a A10BD02 12,895,200 11,573,430 −10.3
Table 2 Number of  international units supplied in the first 12 months of the SNTP Program (free of charge) and in the 
12 months before to the Program (copayment system)
Brazil, February 2010 through January 2012
Adapted from information published [12]
ATC Anatomical therapeutic chemical
a  Both drugs are included in the combination SNTP Program at the same concentrations
Medicines ATC Feb. 2010–Jan. 2011 Feb. 2011–Jan. 2012 Percentage 
of charge
Medicines included in SNTP Program
 Regular human insulin A10AB01 1,122,987 2,221,324 97.8
 Isophane insulin (NPH) A10AC01 11,435,131 20,352,054 78.0
Medicines not included in SNTP Program
 Single‑drug formulations
  Insulin glulisine A10AB06 429,221 575,883 34.2
  Insulin detemir A10AE05 1,644,945 1,864,980 13.4
  Insulin lispro A10AC04 1,278,932 1,396,643 9.2
  Insulin aspart A10AB05 1,554,705 1,696,280 9.1
  Insulin glargine A10AE04 3,328,109 3,533,336 9.1
Fixed‑dose combinations
 Regular human insulin + isophane 
insulin (NPH)a
A10AD30 626,589 595,233 −5.0
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government was responsible for approximately 90  % of 
the cost of some antidiabetic and antihypertensive medi-
cines. From 2011, the government began to pay the full 
cost of medications included in the SNTP program [9, 
10]. The considerable increase in the number of antihy-
pertensive medicines supplied during the implementa-
tion of the SNTP Program [14] confirms, once again, that 
the price of the medicine is an essential determinant of 
the economic accessibility and financial sustainability for 
individuals [15].
Mortality due to diabetes declined in Brazil over the 
15  years between 1996 and 2011, minimally in men but 
considerably in women [16]. However, recent studies have 
shown a high prevalence of diabetes in Brazilian adults 
over time (11.9 %), with a progressive increase in the last 
35  years [17]. It is estimated that hospitalization due to 
diabetes is responsible for 2.2 % of the Ministry of Health 
budget [18], and that 80 % of patients diagnosed with dia-
betes in the country (approximately 7.5 million) are assisted 
by SUS. Further, 57.4 % of patients with diabetes aged over 
18 years received at least one medication for diabetes treat-
ment in the Brazilian SNTP program in 2013 [18–20].
The number of dispensed units of oral antidiabetic 
medications included in the SNTP Program was eight 
times higher than the growth in the pharmaceutical mar-
ket in Brazil during the same period (12.7 %). The highest 
percentage increase in oral antidiabetics was observed 
for 5 mg glibenclamide (65.9 %). The highest variation in 
the number of tablets was for 500 mg metformin, with an 
increase of over 135 million tablets compared with the 
12  months preceding the implementation of the SNTP 
Program.
The insulin medications included in the SNTP Program 
showed the greatest significant changes in the number of 
international units dispensed. The increase was 97.8  % 
for regular human insulin and 78.0 % for isophane insulin 
(NPH). Among the antidiabetic medications not included 
in the SNTP program, only insulin glulisine significantly 
increased (34.2  %), but this increase was still less than 
the growth observed for the insulin types included in the 
program.
Despite the observed increase in the number of inter-
national units of insulin analogues dispensed, health 
technology assessments conducted by the National 
Technology Implementation Commission (Comissão 
Nacional de Incorporação de Tecnologias-Conitec) for 
SUS in 2013, recommended against the inclusion of the 
fast-acting insulin analogues (lispro, aspart and glulisine) 
for the treatment of type 1 diabetes [21] and the long-act-
ing insulin analogues (detemir and glargine) for the treat-
ment of types 1 and 2 diabetes patients [22].
It is important to note that a limitation of the results of 
this study did not include medicines used in hospital or 
dispensed for free at pharmacies of the Brazilian Public 
Health System, which according to Gialdi [23], represent 
approximately 30  % of medication consumption in Bra-
zil. This study also did not address the economic aspects 
such as the amount reimbursed by the State to private 
pharmacies, which has been criticized for being much 
higher than the amount paid for the purchase of the 
same medications for distribution in the Brazilian Public 
Health System.
Conclusions
The results of this study reveal that the SNTP Program 
has significantly contributed to an increase in access to 
medications for the treatment of diabetes, indicating that 
this public health policy has achieved its goal.
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